<DOC>
	<DOCNO>NCT02211846</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics well safety tolerability mirabegron OCAS tablets single-dose administration different dose level child adolescent NDO OAB .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety Tolerability Mirabegron OCAS ( Oral Controlled Absorption System ) Pediatric Subjects With Neurogenic Detrusor Overactivity Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject document diagnosis : Neurogenic detrusor overactivity ( NDO ) , Idiopathic overactive bladder ( OAB ) accord International Children 's Continence Society ( ICCS ) criterion . Subject 's weight/height : Subject body weight ≥ 20.0 kg ( cohort ) . For NDO : subject suffer malnutrition severely overweight , opinion Investigator . For OAB : subject 's weight height within normal percentile ( 3rd 97th percentile ) accord Centers Disease Control Prevention ( CDC ) growth chart . Subject able swallow study medication accordance protocol . Female subject must either : Be nonchildbearing potential : Clearly premenarchal judgment Investigator premenarchal Documented surgically sterile . Or , childbearing potential : Agree try become pregnant study 28 day final study drug administration , And negative urine pregnancy test predose Day 1 , And , heterosexually active agree consistently use two form highly effective form birth control start screen throughout study period 28 day final study drug administration . Female subject must agree breastfeed start screen throughout study period , 28 day last study drug administration . Female subject must donate ovum start screen throughout study period , 28 day final study drug administration . Male subject female spouse/partner childbearing potential must use highly effective form contraception consist two form birth control ( one must barrier method ) start screen continue throughout study period , 28 day final study drug administration . Male subject must donate sperm start Screening throughout study period , 90 day study drug administration . Subject subject 's parent ( ) /legal guardian agree subject participate another interventional study treatment . Subject subject 's parent ( ) /legal guardian willing able comply study requirement concomitant medication restriction Exclusion Criteria At Screening : Subject pregnant . Subject known history QTc prolongation risk QT prolongation ( e.g . hypokalemia , family history Long QT Syndrome ) . Subject abnormal ( mean ) pulse rate accord range specify : age 5 less 8 year : &lt; 60 bpm &gt; 110 bpm ; age 8 less 12 year : &lt; 55 bpm &gt; 100 bpm ; age 12 less 18 year : &lt; 50 bpm &gt; 100 bpm . Subject clinically significant ECG abnormality . Subject mean systolic blood pressure great 95th percentile accord age height and/or great 140 mmHg [ National Institute Health , 2005 ] . Subject clinically significant unstable medical condition disorder , opinion Investigator , preclude subject participate study . Subject aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great equal 2 time upper limit normal ( ULN ) total bilirubin great equal 1.5 time ULN . Subject severe renal impairment ( estimate glomerular filtration rate ( MDRD ) &lt; 30 mL/min ) . Subject clinically significant range result urinalysis , biochemistry hematology . Subject history current diagnosis malignancy . Subject know suspected hypersensitivity mirabegron , ß3agonists , excipients use OCAS tablet formulation previous severe hypersensitivity drug . Subject meet contraindication precaution use mirabegron mention Investigator 's Brochure ( IB ) . Subject use mirabegron past ( last intake less 12 day plan reference day ( Day 4 Day 1 ) . Subject require ongoing treatment follow prohibited medication : Any anticholinergic/antimuscarinic drug within 5 halflives prior plan reference day ( Day 4 Day 1 ) . Any drug sensitive CYP2D6 substrates narrow therapeutic index ( thioridazine , flecainide , propafenone , imipramine , desipramine ) sensitive Pgp substrate ( digoxin , dabigatran ) within 5 halflives prior plan reference day ( Day 4 Day 1 ) . Any moderate strong cytochrome CYP3A4/5 Pgp inhibitor inducer include natural herbal remedy ( itraconazole , rifampicin , phenytoin , carbamazepine , St. John 's Wort , grapefruit , Seville orange ) within 5 halflives prior plan reference day ( Day 4 Day 1 ) . Subject positive urinary drug screen test drug abuse . Subject donate blood blood product within 3 month prior plan Day 1 . Subject participate another clinical trial and/or take investigational drug within 30 day ( 5 halflives investigational drug , whichever long ) prior plan reference day ( Day 4 Day 1 ) . Subject 's parent ( ) /legal guardian employee Astellas Group , Contract Research Organization ( CRO ) involve , Investigator site execute study . Subject current , untreated constipation ( fecal impaction NDO patient ) . If constipation consistently treat last month , subject include . Subject administer intradetrusor botulinum toxin injection ; except give &gt; 4 month prior screen symptom reappear comparable botulinum toxin injection . Exclusion Criteria At day 1 : Subject positive urinary drug screen test drug abuse . Subject positive alcohol breath test . Subject use mirabegron past ( last intake less 24 day plan reference day ( Day 4 Day 1 ) . Subject require ongoing treatment follow prohibited medication : Any anticholinergics/antimuscarinics within 5 halflives prior intake reference day ( Day 4 Day 1 ) . Any drug sensitive CYP2D6 substrates narrow therapeutic index ( thioridazine , flecainide , propafenone , imipramine , desipramine ) sensitive Pgp substrate ( digoxin , dabigatran ) within 5 halflives prior reference day ( Day 4 Day 1 ) . Any moderate strong cytochrome CYP3A4/5 Pgp inhibitor inducer include natural herbal remedy ( itraconazole , rifampicin , phenytoin , carbamazepine , St. John 's Wort ) within 5 halflives prior reference day ( Day 4 Day 1 ) . Subject donate blood blood product within 3 month prior Day 1 . Subject ( female subject childbearing potential ) positive urinary pregnancy test . Subject current symptomatic urinary tract infection .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Neurogenic detrusor overactivity ( NDO )</keyword>
	<keyword>Overactive bladder ( OAB )</keyword>
</DOC>